Andy is a partner on the bio investment team, where he focuses on companies at the intersection of biology, engineering, and healthcare.
Prior to joining a16z, Andy worked in Genentech’s Discovery Oncology department, where he developed high-throughput, genome-wide screens and computational tools for identifying novel cancer targets. Before that, Andy worked with Professor George Church at the Harvard Medical School/Wyss Institute, where he engineered CRISPR genome editing technologies for therapeutic applications. Andy also analyzed high-growth technology companies in the investment banking division of Morgan Stanley.
Andy studied Bioengineering and Computer Science at Harvard University, where he focused on genomics and machine learning. He was awarded the First Place Grand Award in Medicine at the Intel International Science and Engineering Fair.
While not searching for the next frontier in bio, Andy enjoys playing the guitar, building computers, and swimming.